Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The aminoglycosides.

R S Edson1, C L Terrell

  • 1Division of Infectious Diseases and Internal Medicine, Mayo Clinic Rochester, Minnesota 55905, USA.

Mayo Clinic Proceedings
|May 13, 1999
PubMed
Summary
This summary is machine-generated.

Aminoglycosides remain vital for treating serious infections caused by enterococci, mycobacteria, and gram-negative bacteria. Single daily dosing offers a safe and effective alternative to traditional multidose regimens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disseminated Mycobacterium abscessus infection manifesting as fever of unknown origin and intra-abdominal lymphadenitis: case report and literature review.

Diagnostic microbiology and infectious disease·2001
Same author

Antifungal agents. Part II. The azoles.

Mayo Clinic proceedings·1999
Same author

Herpetic whitlow of the toe: an unusual manifestation of infection with herpes simplex virus type 2.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1998
Same author

Localized soft-tissue infections with Mycobacterium avium/Mycobacterium intracellulare complex in immunocompetent patients: granulomatous tenosynovitis of the hand or wrist.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1995
Same author

74-year-old woman with dyspnea, fever, and cough.

Mayo Clinic proceedings·1995
Same author

Coccidioidomycosis with necrotizing granulomatous conjunctivitis.

Cornea·1994
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
Same journal

Chronic Kidney Disease-In the Limelight, July 2026.

Mayo Clinic proceedings·2026
Same journal

In Reply: Long-Term Cardiovascular Burden After Carotid Endarterectomy: Moving Beyond Conventional Risk Profiling.

Mayo Clinic proceedings·2026
Same journal

Long-Term Cardiovascular Burden After Carotid Endarterectomy: Moving Beyond Conventional Risk Profiling.

Mayo Clinic proceedings·2026
Same journal

Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study.

Mayo Clinic proceedings·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Aminoglycosides are crucial for treating severe enterococcal, mycobacterial, and gram-negative bacillary infections.
  • Gentamicin is a cost-effective choice for specific infections, often used with beta-lactam antibiotics.
  • Amikacin and streptomycin are valuable for resistant gram-negative bacilli, Nocardia, nontuberculous mycobacteria, and multidrug-resistant tuberculosis.

Purpose of the Study:

  • To review the current role of aminoglycosides in treating serious bacterial infections.
  • To discuss the utility of specific aminoglycosides like gentamicin, amikacin, and streptomycin.
  • To evaluate the safety and efficacy of single daily dosing regimens for aminoglycosides.

Main Methods:

  • Literature review of aminoglycoside use in clinical practice.

Related Experiment Videos

  • Analysis of resistance patterns in enterococci and gram-negative bacilli.
  • Evaluation of single daily dosing versus traditional multidose regimens.

    • Main Results:

    • Aminoglycosides remain essential despite newer agents, with varying resistance patterns.
    • Gentamicin is preferred where resistance is low; amikacin and streptomycin address resistant strains.
    • Single daily dosing appears as safe and effective as traditional regimens, offering convenience and cost-effectiveness.

    Conclusions:

    • Aminoglycosides continue to be indispensable in managing specific serious bacterial infections.
    • Resistance patterns necessitate careful selection of aminoglycosides.
    • Single daily dosing represents a promising strategy for aminoglycoside therapy.